Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03628534 · ClinicalTrials.gov registry record · NA
SERF VT Ablation Early Feasibility Study (EFS)
A NA study, sponsored by Thermedical.
- Completed
- Registry status
- NA
- Development phase
- 16
- Enrollment target
NCT03628534: Completed NA study, sponsored by Thermedical.
NCT03628534 is a NA study that has completed, run by Thermedical. The registered enrollment target is 16 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03628534, a NA study, has completed, sponsored by Thermedical.
- COMPLETED
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is an early feasibility, non-randomized, open-label, single group, interventional study to be conducted in up to 20 US subjects to evaluate the technical feasibility of the Durablate Catheter and Thermedical Ablation System to eliminate or control sustained, monomorphic ventricular tachycardia (VT) in patients with VT refractory to drug and conventional catheter ablation with acceptable procedural safety.
Primary Outcome
Completion of intended ablation during treatment setting as measured by non-inducibility of the targeted clinical VT (acute procedural success).
Interventions
- DEVICE Saline Enhanced Radiofrequency (SERF) ablation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-11-01 |
| Est. Completion | 2022-07-31 |
| Phase | NA |
What the finished NCT03628534 record still lists
NCT03628534 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Saline Enhanced Radiofrequency (SERF) ablation is the first listed.
NCT03628534 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03628534 about?
NCT03628534 is a clinical study titled "SERF VT Ablation Early Feasibility Study (EFS)". This is an early feasibility, non-randomized, open-label, single group, interventional study to be conducted in up to 20 US subjects to evaluate the technical feasibility of the Durablate Catheter and Thermedical Ablation System to eliminate or control sustained, monomorphic ventricular tachycardia ...
What is the current status of trial NCT03628534?
This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2018-11-01. Estimated completion is 2022-07-31.
What interventions are being tested in trial NCT03628534?
The interventions under investigation include: Saline Enhanced Radiofrequency (SERF) ablation (DEVICE).
Who is sponsoring clinical trial NCT03628534?
This trial is sponsored by Thermedical, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03628534's enrollment target sits among peer trials
16 1871st of 2000 higher than 120 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI